CAMBRIDGE: One of the businesses within the race to develop a vaccine to remedy the novel and lethal coronavirus has introduced that its drug candidate underneath trial indicated a 94.1% efficacy in opposition to COVID-19 and 100% efficacy in extreme circumstances.
According to a press launch issued Monday, American biotechnology firm Moderna stated its coronavirus drug candidate — mRNA-1273 — was “generally well tolerated” and that had “no serious safety concerns”.
The Massachusetts-based firm’s Phase 3 COVE examine of the coronavirus vaccine had 30,000 contributors and 196 circumstances of COVID-19, of which 30 had been recognized as extreme.
The press launch additional said that Moderna would submit a request later immediately to the US Food and Drug Administration (FDA) for the Emergency Use Authorization (EUA) approval of its coronavirus vaccine.
Moderna stated it additionally meant “to apply for a conditional marketing authorization with the European Medicines Agency (EMA) and to progress with the rolling reviews, which have already been initiated with international regulatory agencies”, as per the press launch.
More to observe…